Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.
|Articles|July 4, 2022
Don’t Miss Our July Issue
Author(s)Psychiatric Times Editors
Our July issue is now live!
Advertisement
The PDF of our July issue is now available to peruse. The articles will roll out over the next few weeks, but if you want a sneak peek, look no further. From cover to cover, this issue is fully of clinical pearls and the latest in psychiatry. Specifically, you can learn more about
-The 988 Suicide Prevention Hotline going live this month
-Anti-NMDA Receptor Encephalitis Pathophysiology
-8 Key Issues in Major Depressive Disorders
-Nonadherence in Schizophrenia
-Updates from conferences
-Managing psychosis
-And much, much more!
Read it all
We hope you enjoy. If you think we’ve missed covering something, feel free to reach out. Write us at
Advertisement
Related to this article
Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.
Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
FDA Shelves Fast-Track Drug Review Initiative
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
5